OBJECTIVE: In this study we attempted to show that the interaction between NOTCH4 and catechol-O-methyltransferase (COMT) polymorphism predicts the response to typical neuroleptics in schizophrenia. Our sample consisted of 94 Finnish patients with DSM-IV schizophrenia and 98 controls. METHODS: Several studies have connected COMT and NOTCH4 genes to schizophrenia. We have previously shown that COMT polymorphism is significantly associated with treatment response in schizophrenia. NOTCH4 SNP2 polymorphism has been associated with age of onset in schizophrenia, but there is also a trend that this polymorphism may predict response to typical neuroleptics. In the present sample, there is a strong gene-gene interaction between these genes (P = 0.003) and they have additive effect in treatment response. RESULTS: Patients carrying both NOTCH4 C/C genotype and COMT low/low genotype, had more than ten times higher risk of being a non-responder than responder to treatment with typical neuroleptics [OR = 10.25 (95% CI 2.21-47.53), P < 0.001]. This combination of genotypes is also more common in patients considered non-responders than in controls [OR = 3.00 (95% CI 1.33-6.76), P = 0.007]. CONCLUSION: Our results suggest that an interaction between COMT and NOTCH4 genotypes may predict the treatment response to typical neuroleptics in patients with schizophrenia. Copyright 2004 Lippincott Williams & Wilkins
OBJECTIVE: In this study we attempted to show that the interaction between NOTCH4 and catechol-O-methyltransferase (COMT) polymorphism predicts the response to typical neuroleptics in schizophrenia. Our sample consisted of 94 Finnish patients with DSM-IV schizophrenia and 98 controls. METHODS: Several studies have connected COMT and NOTCH4 genes to schizophrenia. We have previously shown that COMT polymorphism is significantly associated with treatment response in schizophrenia. NOTCH4 SNP2 polymorphism has been associated with age of onset in schizophrenia, but there is also a trend that this polymorphism may predict response to typical neuroleptics. In the present sample, there is a strong gene-gene interaction between these genes (P = 0.003) and they have additive effect in treatment response. RESULTS:Patients carrying both NOTCH4 C/C genotype and COMT low/low genotype, had more than ten times higher risk of being a non-responder than responder to treatment with typical neuroleptics [OR = 10.25 (95% CI 2.21-47.53), P < 0.001]. This combination of genotypes is also more common in patients considered non-responders than in controls [OR = 3.00 (95% CI 1.33-6.76), P = 0.007]. CONCLUSION: Our results suggest that an interaction between COMT and NOTCH4 genotypes may predict the treatment response to typical neuroleptics in patients with schizophrenia. Copyright 2004 Lippincott Williams & Wilkins
Authors: Anna C Need; Richard S E Keefe; Dongliang Ge; Iris Grossman; Sam Dickson; Joseph P McEvoy; David B Goldstein Journal: Eur J Hum Genet Date: 2009-01-21 Impact factor: 4.246
Authors: C J Zheng; L Y Han; B Xie; C Y Liew; S Ong; J Cui; H L Zhang; Z Q Tang; S H Gan; L Jiang; Y Z Chen Journal: Nucleic Acids Res Date: 2006-12-06 Impact factor: 16.971
Authors: Eric Huang; Clement C Zai; Amanda Lisoway; Malgorzata Maciukiewicz; Daniel Felsky; Arun K Tiwari; Jeffrey R Bishop; Masashi Ikeda; Patricio Molero; Felipe Ortuno; Stefano Porcelli; Jerzy Samochowiec; Pawel Mierzejewski; Shugui Gao; Benedicto Crespo-Facorro; José M Pelayo-Terán; Harpreet Kaur; Ritushree Kukreti; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Daniel J Müller; James L Kennedy Journal: Int J Neuropsychopharmacol Date: 2016-04-29 Impact factor: 5.176
Authors: Antonio Rampino; Aleksandra Marakhovskaia; Tiago Soares-Silva; Silvia Torretta; Federica Veneziani; Jean Martin Beaulieu Journal: Front Psychiatry Date: 2019-01-09 Impact factor: 4.157